Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 2.860
+0.040 (1.42%)
Aug 28, 2026, 10:23 AM AEST
Australian Clinical Labs Ratios and Metrics
Market cap in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 522 | 416 | 540 | 503 | 694 | 922 | |
Market Cap Growth | 0.50% | -23.08% | 7.36% | -27.51% | -24.69% | 34.33% |
Enterprise Value | 834 | 708 | 834 | 805 | 1,001 | 1,160 |
Last Close Price | 2.82 | 2.24 | 2.65 | 2.30 | 3.04 | 3.63 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 22.87 | 17.53 | 16.66 | 21.03 | 19.34 | 5.17 |
Forward PE | 15.03 | 12.66 | 13.94 | 13.83 | 15.92 | 9.64 |
PS Ratio | 0.71 | 0.56 | 0.73 | 0.72 | 1.00 | 0.93 |
PB Ratio | 3.48 | 2.78 | 3.14 | 2.83 | 4.02 | 3.96 |
P/TBV Ratio | - | - | 87.92 | 39.99 | 95.82 | 13.75 |
P/FCF Ratio | 3.39 | 2.70 | 3.10 | 3.29 | 5.08 | 3.51 |
P/OCF Ratio | 3.20 | 2.55 | 2.96 | 3.15 | 4.83 | 3.25 |
PEG Ratio | 2.22 | 2.56 | 0.74 | 3.00 | 0.78 | 0.78 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 1.13 | 0.96 | 1.13 | 1.16 | 1.44 | 1.17 |
EV/EBITDA Ratio | 4.07 | 8.65 | 10.26 | 10.55 | 12.56 | 4.05 |
EV/EBIT Ratio | 11.99 | 10.18 | 12.27 | 12.87 | 15.35 | 4.24 |
EV/FCF Ratio | 5.42 | 4.61 | 4.79 | 5.26 | 7.32 | 4.42 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 2.25 | 2.25 | 1.69 | 1.74 | 1.83 | 1.13 |
Debt / EBITDA Ratio | 1.65 | 1.65 | 1.42 | 1.62 | 1.68 | 0.69 |
Debt / FCF Ratio | 2.19 | 2.19 | 1.67 | 2.02 | 2.31 | 1.00 |
Net Debt / Equity Ratio | 2.08 | 2.08 | 1.56 | 1.59 | 1.71 | 1.01 |
Net Debt / EBITDA Ratio | 3.81 | 3.81 | 3.30 | 3.70 | 3.71 | 0.82 |
Net Debt / FCF Ratio | 2.03 | 2.03 | 1.54 | 1.84 | 2.16 | 0.89 |
Asset Turnover | 1.26 | 1.26 | 1.27 | 1.19 | 1.16 | 1.79 |
Inventory Turnover | 31.14 | 31.14 | 28.99 | 27.72 | 25.32 | 32.71 |
Quick Ratio | 0.44 | 0.44 | 0.44 | 0.52 | 0.51 | 0.53 |
Current Ratio | 0.54 | 0.54 | 0.56 | 0.64 | 0.62 | 0.64 |
Return on Equity (ROE) | 14.93% | 14.93% | 18.77% | 13.84% | 17.79% | 113.46% |
Return on Assets (ROA) | 7.45% | 7.45% | 7.28% | 6.67% | 6.75% | 30.79% |
Return on Invested Capital (ROIC) | 9.68% | 9.91% | 10.29% | 8.98% | 10.40% | 46.95% |
Return on Capital Employed (ROCE) | 18.20% | 18.20% | 19.00% | 16.20% | 16.70% | 68.00% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 27, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 4.54% | 5.71% | 6.00% | 4.76% | 5.17% | 19.34% |
FCF Yield | 29.46% | 36.99% | 32.28% | 30.42% | 19.70% | 28.51% |
Dividend Yield | 4.39% | 5.80% | 4.72% | 5.23% | 4.61% | 14.59% |
Payout Ratio | 105.43% | 103.72% | 76.92% | 83.35% | 269.85% | 13.59% |
Buyback Yield / Dilution | 3.87% | 3.87% | -0.30% | 0.82% | 0.18% | -32.47% |
Total Shareholder Return | 8.26% | 9.67% | 4.42% | 6.04% | 4.79% | -17.87% |